AI assistant
Onxeo — Share Issue/Capital Change 2014
Jul 3, 2014
1573_dva_2014-07-03_9bfd29ac-a198-46d8-b223-ce9ff50b538e.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disclosure of total number of voting rights and number of shares in the capital at June 30, 2014
Paris, July 3, 2014 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):
| Date | Total number of outstanding shares |
Total number of voting rights |
|---|---|---|
| June 30, 2014 | 20, 682, 992 | Theoretical number of voting rights: 20, 682, 992 (including treasury shares) Number of real voting rights: 20, 654, 050 (without treasury shares) |
About BioAlliance Pharma
Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product portfolio:
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going Validive® (Clonidine Lauriad® ) (mucositis): Phase II on going Biotherapy AMEP® /Synfoldin (invasive melanoma): Preclinical and clinical Phase For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
BioAlliance Pharma SA ALIZE RP
Judith Gréciet, CEO Caroline Carmagnol Tel.: +33 1 45 58 76 01 Tel.: +33 6 64 18 99 59 [email protected] [email protected]
Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 [email protected]